JP2010521516A5 - - Google Patents

Download PDF

Info

Publication number
JP2010521516A5
JP2010521516A5 JP2009554019A JP2009554019A JP2010521516A5 JP 2010521516 A5 JP2010521516 A5 JP 2010521516A5 JP 2009554019 A JP2009554019 A JP 2009554019A JP 2009554019 A JP2009554019 A JP 2009554019A JP 2010521516 A5 JP2010521516 A5 JP 2010521516A5
Authority
JP
Japan
Prior art keywords
pain
compound
treatment
formula
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2009554019A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010521516A (ja
Filing date
Publication date
Priority claimed from GB0705424A external-priority patent/GB0705424D0/en
Priority claimed from GB0712390A external-priority patent/GB0712390D0/en
Application filed filed Critical
Priority claimed from PCT/EP2008/053285 external-priority patent/WO2008113818A1/en
Publication of JP2010521516A publication Critical patent/JP2010521516A/ja
Publication of JP2010521516A5 publication Critical patent/JP2010521516A5/ja
Ceased legal-status Critical Current

Links

JP2009554019A 2007-03-21 2008-03-19 疼痛および過敏性腸症候群の治療におけるキノリン誘導体の使用 Ceased JP2010521516A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0705424A GB0705424D0 (en) 2007-03-21 2007-03-21 Use of compounds in the treatment of pain and irritable bowel syndrome
GB0712390A GB0712390D0 (en) 2007-06-26 2007-06-26 Use of compounds in the treatment of pain and irritable bowel syndrome
PCT/EP2008/053285 WO2008113818A1 (en) 2007-03-21 2008-03-19 Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome

Publications (2)

Publication Number Publication Date
JP2010521516A JP2010521516A (ja) 2010-06-24
JP2010521516A5 true JP2010521516A5 (https=) 2011-04-28

Family

ID=39564633

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009554019A Ceased JP2010521516A (ja) 2007-03-21 2008-03-19 疼痛および過敏性腸症候群の治療におけるキノリン誘導体の使用

Country Status (5)

Country Link
US (1) US20100041672A1 (https=)
EP (1) EP2120950B1 (https=)
JP (1) JP2010521516A (https=)
ES (1) ES2389958T3 (https=)
WO (1) WO2008113818A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004000260T2 (de) 2003-07-22 2006-08-24 Arena Pharmaceuticals, Inc., San Diego Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
UA97837C2 (ru) 2007-03-23 2012-03-26 Эбботт Гмбх Унд Ко. Кг Соединения хинолина для лечения нарушений, которые реагируют на модуляцию рецептора серотонина 5-ht6
EP2508177A1 (en) 2007-12-12 2012-10-10 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
WO2013055386A2 (en) 2011-10-03 2013-04-18 The University Of Utah Research Foundation Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
EP2822641B1 (en) * 2012-03-08 2019-06-19 SPR Therapeutics, Inc. System for treatment of pain related to limb joint replacement surgery
US20160038484A1 (en) * 2013-04-03 2016-02-11 The University Of Utah Research Foundation Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
US10022355B2 (en) 2015-06-12 2018-07-17 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder
BR112018000728A2 (pt) 2015-07-15 2018-09-04 Axovant Sciences Gmbh resumo método para a profilaxia e/ou tratamento de alucinações visuais em um sujeito com necessidade do mesmo
CN109069450A (zh) * 2016-02-05 2018-12-21 法奈克斯公司 神经障碍的新的组合疗法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5596001A (en) * 1993-10-25 1997-01-21 Pfizer Inc. 4-aryl-3-(heteroarylureido)quinoline derivatves
US5576338A (en) * 1995-02-15 1996-11-19 Merck Frosst Canada, Inc. Bis (biaryl) compounds as inhibitors of leukotriene biosynthesis
US20010051719A1 (en) * 1996-12-19 2001-12-13 Smithkline Beecham P.L.C. Novel compounds
US6207679B1 (en) * 1997-06-19 2001-03-27 Sepracor, Inc. Antimicrobial agents uses and compositions related thereto
US6172084B1 (en) * 1997-06-19 2001-01-09 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
US6376670B1 (en) * 1997-06-19 2002-04-23 Sepracor Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
EP0994862B1 (en) * 1997-07-11 2005-06-01 SmithKline Beecham plc Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation
GB9801392D0 (en) * 1998-01-22 1998-03-18 Smithkline Beecham Plc Novel compounds
GB9818916D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
GB9820113D0 (en) * 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
US6403808B1 (en) * 1999-12-10 2002-06-11 Virginia Commonwealth University Selective 5-HT6 receptor ligands
US6310212B1 (en) * 2000-03-28 2001-10-30 Neurogen Corporation 4-substituted quinoline derivatives
GB0021450D0 (en) * 2000-08-31 2000-10-18 Smithkline Beecham Plc Novel compounds
KR100823908B1 (ko) * 2000-10-20 2008-04-21 바이오비트럼 에이비(피유비엘) 2-, 3-, 4-, 또는 5-치환-n1-(벤젠술포닐)인돌 및 이의치료 용도
DE10053813A1 (de) * 2000-10-30 2002-05-08 Bayer Ag Neue Verwendung von Sulfonamiden
US6849644B2 (en) * 2000-11-21 2005-02-01 Smithkline Beecham P.L.C. Isoquinoline derivatives useful in the treatment of CNS disorders
WO2002041889A2 (en) * 2000-11-24 2002-05-30 Smithkline Beecham P.L.C. Indolsulfonyl compounds useful in the treatment of cns disorders
BR0210929A (pt) * 2001-06-07 2004-06-08 Hoffmann La Roche Derivados de indol com afinidade para o receptor 5-ht6
ITRM20010356A1 (it) * 2001-06-21 2002-12-23 Sigma Tau Ind Farmaceuti "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
JP2005518414A (ja) * 2001-12-21 2005-06-23 スミスクライン ビーチャム パブリック リミテッド カンパニー ドーパミン受容体のモジュレーターとしての7−スルホニル−3−ベンゾアゼピン誘導体およびcns障害の治療のためのその使用
WO2003065046A2 (en) * 2002-02-01 2003-08-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor
GB0202679D0 (en) * 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
ATE323680T1 (de) * 2002-02-13 2006-05-15 Glaxo Group Ltd 7-arylsulfonamid-2,3,4,5-tetrahydro-1h- benzo¬däazepine mit 5-ht6 rezeptor affinität zur behandlung von zentralnervensystemerkrankungen
RU2309154C9 (ru) * 2002-03-27 2016-09-27 Глэксо Груп Лимитед 3-фенилсульфонил-8-пиперазин-1-ил-хинолины, обладающие аффинностью к 5-нт6 рецептору, способы их получения (варианты)
JP4754821B2 (ja) * 2002-06-20 2011-08-24 プロキシマゲン・リミテッド 肥満症、ii型糖尿病およびcns障害の治療に有用な新規化合物
WO2004050085A1 (en) * 2002-12-03 2004-06-17 F. Hoffmann-La Roche Ag Aminoalkoxyindoles as 5-ht6-receptor ligands for the treatment of cns-disorders
WO2004074286A1 (en) * 2003-02-14 2004-09-02 Wyeth Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands
GB0305575D0 (en) * 2003-03-11 2003-04-16 Glaxo Group Ltd Novel compounds
GB0321473D0 (en) * 2003-09-12 2003-10-15 Glaxo Group Ltd Novel compounds
GB0322510D0 (en) * 2003-09-25 2003-10-29 Glaxo Group Ltd Novel compounds
GB0322629D0 (en) * 2003-09-26 2003-10-29 Glaxo Group Ltd Novel compound
SE0302760D0 (sv) * 2003-10-20 2003-10-20 Biovitrum Ab New compounds
WO2005066157A1 (en) * 2004-01-02 2005-07-21 Suven Life Sciences 3-(pyrolidin-3-l) indoles as 5-ht6 receptor modulators
GB0407025D0 (en) * 2004-03-29 2004-04-28 Glaxo Group Ltd Novel compounds
GB0411421D0 (en) * 2004-05-21 2004-06-23 Glaxo Group Ltd Novel compounds
KR20070034049A (ko) * 2004-06-09 2007-03-27 글락소 그룹 리미티드 피롤로피리딘 유도체
GB0425548D0 (en) * 2004-11-19 2004-12-22 Glaxo Group Ltd Radiolabelled ligands

Similar Documents

Publication Publication Date Title
JP2010521516A5 (https=)
JP2011518833A5 (https=)
JP2016522835A5 (https=)
JP2013523733A5 (https=)
JP2011528658A5 (https=)
JP2015512931A5 (https=)
JP2013537203A5 (https=)
JP2013500986A5 (https=)
JP2017528503A5 (https=)
JP2017531038A5 (https=)
JP2009502743A5 (https=)
JP2017520613A5 (https=)
JP2014521744A5 (https=)
JP2013542261A5 (https=)
JP2011513410A5 (https=)
JP2007302689A5 (https=)
JP2015508092A5 (https=)
JP2015521156A5 (https=)
JP2017511377A5 (https=)
JP2015516419A5 (https=)
JP2013506674A5 (https=)
JP2008513510A5 (https=)
JP2012509265A5 (https=)
JP2011515406A5 (https=)
JP2012511558A5 (https=)